| Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] | Technology appraisal guidance |
| Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years
[TSID12142] | Technology appraisal guidance |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108] | Technology appraisal guidance |
| Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476] | Technology appraisal guidance |
| Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481] | Technology appraisal guidance |
| Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769] | Technology appraisal guidance |
| Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322] | Technology appraisal guidance |
| Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344] | Technology appraisal guidance |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537] | Technology appraisal guidance |
| Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465] | Technology appraisal guidance |
| BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446] | Technology appraisal guidance |
| Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384] | Technology appraisal guidance |
| Bimekizumab for treating ankylosing spondylitis [TSID10334] | Technology appraisal guidance |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991] | Technology appraisal guidance |
| Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592] | Technology appraisal guidance |
| Botulinum toxin type A for preventing episodic migraine [ID6450] | Technology appraisal guidance |
| Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448] | Technology appraisal guidance |
| Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437] | Technology appraisal guidance |
| Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486] | Technology appraisal guidance |
| Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [TSID12082] | Technology appraisal guidance |
| Bupivacaine–meloxicam for treating postoperative pain [ID2728] | Technology appraisal guidance |
| Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731] | Technology appraisal guidance |
| Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387] | Technology appraisal guidance |
| CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210] | Technology appraisal guidance |
| Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation
[ID6535] | Technology appraisal guidance |